{"log_id": 6700084288777952487, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 2e-06, "average": 0.999112, "min": 0.993935}, "location": {"width": 782, "top": 200, "height": 32, "left": 225}, "words": "迟发性心脏毒性的发生并无预示作用,很少有临床意义,而且通常无需为此停止伊"}, {"probability": {"variance": 0, "average": 0.999761, "min": 0.999589}, "location": {"width": 107, "top": 248, "height": 27, "left": 226}, "words": "达比星治疗"}, {"probability": {"variance": 1.2e-05, "average": 0.998061, "min": 0.982385}, "location": {"width": 790, "top": 310, "height": 30, "left": 228}, "words": "晚期(即迟发)事件迟发性心脏毒性通常在治疗后期或在治疗结束后2至3个月内"}, {"probability": {"variance": 5e-06, "average": 0.998845, "min": 0.989897}, "location": {"width": 785, "top": 351, "height": 34, "left": 225}, "words": "发生,但也有报道在治疗结束后数月到数年出现的迟发性事件。迟发性心肌病可表"}, {"probability": {"variance": 9.2e-05, "average": 0.995835, "min": 0.945308}, "location": {"width": 783, "top": 393, "height": 35, "left": 225}, "words": "现为左心室射血分数(LVEF)降低和或充血性心力衰竭(CHF)的症状和体征,如呼吸"}, {"probability": {"variance": 6e-06, "average": 0.998953, "min": 0.986629}, "location": {"width": 785, "top": 435, "height": 36, "left": 226}, "words": "困难、肺水肿、坠积性水肿、心脏肥大、肝脏肿大、少尿、腹水、胸腔积液和奔马"}, {"probability": {"variance": 0.002873, "average": 0.989803, "min": 0.668747}, "location": {"width": 791, "top": 476, "height": 37, "left": 226}, "words": "律。也有亚急性症状,如心包炎/心肌炎的报道。蒽环类药物引起的最严重的心肌病"}, {"probability": {"variance": 1e-06, "average": 0.999289, "min": 0.99584}, "location": {"width": 586, "top": 521, "height": 34, "left": 228}, "words": "为危及生命的充血性心力衰竭,是药物的累积剂量限制性毒性"}, {"probability": {"variance": 1e-06, "average": 0.999202, "min": 0.995289}, "location": {"width": 786, "top": 582, "height": 38, "left": 228}, "words": "尚未规定静脉注射或口服伊达比星的累积剂量上限。但据报道,接受静脉注射剂量"}, {"probability": {"variance": 2e-05, "average": 0.997632, "min": 0.976145}, "location": {"width": 772, "top": 625, "height": 38, "left": 229}, "words": "累积达150-290mg/m2的患者中有5%发生与伊达比星相关的心肌病。现有的数据"}, {"probability": {"variance": 1e-05, "average": 0.998432, "min": 0.983841}, "location": {"width": 783, "top": 666, "height": 40, "left": 229}, "words": "显示,口服伊达比星总累积剂量可达400mg/m2,提示其导致心脏毒性的可能性较"}, {"probability": {"variance": 0, "average": 0.999898, "min": 0.999898}, "location": {"width": 21, "top": 723, "height": 23, "left": 231}, "words": "小"}, {"probability": {"variance": 0.000166, "average": 0.997427, "min": 0.921353}, "location": {"width": 785, "top": 775, "height": 36, "left": 230}, "words": "在使用伊达比星治疗前,需要进行心脏功能的评估,而且在整个治疗期间需要监测"}, {"probability": {"variance": 3.2e-05, "average": 0.998306, "min": 0.966351}, "location": {"width": 777, "top": 815, "height": 40, "left": 232}, "words": "心脏功能,以尽可能地减少发生严重心脏功能损害的风险。在治疗期间定期监测"}, {"probability": {"variance": 0.002175, "average": 0.989539, "min": 0.706449}, "location": {"width": 787, "top": 857, "height": 40, "left": 232}, "words": "室射血分数(LVEF),一旦出现心脏功能损害的表现立即停用伊达比星就可能减小发"}, {"probability": {"variance": 0, "average": 0.737935, "min": 0.737935}, "location": {"width": 30, "top": 895, "height": 21, "left": 996}, "words": "电"}, {"probability": {"variance": 0.004015, "average": 0.981226, "min": 0.640578}, "location": {"width": 777, "top": 899, "height": 51, "left": 234}, "words": "生的风险。可以运用MUGA扫描(多门核素血管造影术)或者超声心动图理音"}, {"probability": {"variance": 0.000352, "average": 0.991996, "min": 0.911283}, "location": {"width": 749, "top": 943, "height": 38, "left": 259}, "words": "ECHO)对心脏功能进行反复的量化评估(对LVEF的评估)。推荐在基线的时"}, {"probability": {"variance": 1.9e-05, "average": 0.997789, "min": 0.975165}, "location": {"width": 772, "top": 986, "height": 38, "left": 234}, "words": "候进行心电图、MUGA扫描或者ECHO检查,特别适合于那些具有高危风险因素"}, {"probability": {"variance": 1.4e-05, "average": 0.998095, "min": 0.980793}, "location": {"width": 778, "top": 1030, "height": 36, "left": 233}, "words": "的患者。应反复进行MUGA扫描或ECHO检查以评估左室射血分数,尤其是在使"}, {"probability": {"variance": 0.000368, "average": 0.994176, "min": 0.893445}, "location": {"width": 765, "top": 1072, "height": 36, "left": 233}, "words": "用高累积剂量蒽环类药物时。这种评估技术在随访期间也应坚持使用。随访过程"}, {"probability": {"variance": 2.5e-05, "average": 0.997989, "min": 0.979266}, "location": {"width": 351, "top": 1119, "height": 30, "left": 235}, "words": "中,用于监测评估的技术要保持一致"}, {"probability": {"variance": 0, "average": 0.999527, "min": 0.997077}, "location": {"width": 783, "top": 1178, "height": 37, "left": 236}, "words": "发生心脏毒性的危险因素包括活动性的或者是非活动性的心血管疾病、目前或既往"}, {"probability": {"variance": 4.8e-05, "average": 0.997341, "min": 0.96781}, "location": {"width": 768, "top": 1221, "height": 36, "left": 237}, "words": "接受过纵膈/心脏周围区域的放射治疗,之前用过其他蒽环类药物或者蒽二酮药物"}, {"probability": {"variance": 2e-06, "average": 0.999182, "min": 0.992015}, "location": {"width": 759, "top": 1262, "height": 39, "left": 242}, "words": "同时使用其他抑制心肌收缩功能的药物或者具有心脏毒性的药物(例如曲妥珠单"}, {"probability": {"variance": 2.4e-05, "average": 0.998504, "min": 0.970402}, "location": {"width": 783, "top": 1305, "height": 37, "left": 240}, "words": "抗)。除非患者的心功能得到严密的监测,否则蒽环类药物包括伊达比星不能与其"}, {"probability": {"variance": 1e-06, "average": 0.999352, "min": 0.996225}, "location": {"width": 785, "top": 1348, "height": 37, "left": 240}, "words": "他具有心脏毒性的药物同时使用。患者在停止使用其他具有心脏毒性的药物(特别"}, {"probability": {"variance": 3e-06, "average": 0.998915, "min": 0.990856}, "location": {"width": 780, "top": 1391, "height": 36, "left": 241}, "words": "是具有长半衰期的药物例如曲妥珠单抗)之后接受蒽环类药物可能也会增加发生心"}, {"probability": {"variance": 0.000147, "average": 0.996457, "min": 0.925993}, "location": {"width": 749, "top": 1433, "height": 37, "left": 240}, "words": "脏毒性的风险。曲妥珠单抗的半衰期约为28.5天并且在血循环中可以持续至24"}, {"probability": {"variance": 0.000334, "average": 0.984912, "min": 0.950958}, "location": {"width": 128, "top": 1545, "height": 22, "left": 315}, "words": "No:20100128"}, {"probability": {"variance": 0.002055, "average": 0.972597, "min": 0.872421}, "location": {"width": 103, "top": 1537, "height": 21, "left": 589}, "words": "第6页共11页"}], "language": 3}